High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia
Restricted accessResearch articleFirst published online March, 2017
High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia
Coreceptor switching from CCR5 to CXCR4 is common during chronic HIV-1 infection, but is even more common in individuals who have failed antiretroviral therapy (ART). Prior studies have suggested rapid mutation and/or recombination of HIV-1 envelope (env) genes during coreceptor switching. We compared the functional and genotypic changes in env of viruses from viremic subjects who had failed ART just before and after coreceptor switching and compared those to viruses from matched subjects without coreceptor switching. Analysis of multiple unique functional env clones from each subject revealed extensive diversity at both sample time points and rapid diversification of sequences during the 4-month interval in viruses from both 9 subjects with coreceptor switching and 15 control subjects. Only two subjects had envs with evidence of recombination. Three findings distinguished env clones from subjects with coreceptor switching from controls: (1) lower entry efficiency via CCR5; (2) longer V1/V2 regions; and (3), lower nadir CD4 T cell counts during prior years of infection. Most of these subjects harbored virus with lower replicative capacity associated with protease (PR) and/or reverse transcriptase inhibitor resistance mutations, and the extensive diversification tended to lead either to improved entry efficiency via CCR5 or the gain of entry function via CXCR4. These results suggest that R5X4 or X4 variants emerge from a diverse, low-fitness landscape shaped by chronic infection, multiple ART resistance mutations, the availability of target cells, and reduced entry efficiency via CCR5.
Get full access to this article
View all access options for this article.
References
1.
BergerEA, MurphyPM, FarberJM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol, 1999; 17:657–700.
2.
ShankarappaR, MargolickJB, GangeSJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol, 1999; 73:10489–10502.
3.
CoetzerM, NedellecR, SalkowitzJ, et al.: Evolution of CCR5 use before and during coreceptor switching. J Virol, 2008; 82:11758–11766.
4.
CocchiF, DeVicoAL, Garzino-DemoA, CaraA, GalloRC, LussoP: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med, 1996; 2:1244–1247.
5.
HwangSS, BoyleTJ, LyerlyHK, CullenBR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science, 1991; 253:71–74.
6.
SpeckRF, WehrlyK, PlattEJ, et al.: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol, 1997; 71:7136–7139.
7.
ShiodaT, LevyJA, Cheng-MayerC: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A, 1992; 89:9434–9438.
8.
LabrosseB, TrebouteC, BrelotA, AlizonM: Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol, 2001; 75:5457–5464.
9.
PastoreC, NedellecR, RamosA, PontowS, RatnerL, MosierDE: Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol, 2006; 80:750–758.
10.
KimFM, KolsonDL, BallietJW, SrinivasanA, CollmanRG: V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate. J Virol, 1995; 69:1755–1761.
11.
HuangW, TomaJ, FransenS, et al.: Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol, 2008; 82:5584–5593.
12.
BazanHA, AlkhatibG, BroderCC, BergerEA: Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol, 1998; 72:4485–4491.
13.
BjorndalA, DengH, JanssonM, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol, 1997; 71:7478–7487.
14.
MooreJP, KitchenSG, PugachP, ZackJA: The CCR5 and CXCR4 coreceptors—Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses, 2004; 20:111–126.
15.
ConnorRI, SheridanKE, CeradiniD, ChoeS, LandauNR: Change in coreceptor use correlates with disease progression in HIV-1—Infected individuals. J Exp Med, 1997; 185:621–628.
16.
MooreJP, KuritzkesDR: A piece de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS, 2009; 4:118–124.
17.
WilkinTJ, SuZ, KuritzkesDR, et al.: HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis, 2007; 44:591–595.
18.
DorrP, WestbyM, DobbsS, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 2005; 49:4721–4732.
19.
FatkenheuerG, PozniakAL, JohnsonMA, et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med, 2005; 11:1170–1172.
20.
WhitcombJM, HuangW, FransenS, et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother, 2007; 51:566–575.
21.
ReevesJCE, PetropoulosC, WhitcombJ: An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry, 2009; 3:94–102.
22.
JensenMA, LiFS, van 't WoutAB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol, 2003; 77:13376–13388.
23.
AbbateI, RozeraG, TommasiC, et al.: Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect, 2011; 17:725–731.
24.
PoonAF, SwensonLC, BunnikEM, et al.: Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data. PLoS Comput Biol, 2012; 8:e1002753.
25.
BunnikEM, SwensonLC, Edo-MatasD, et al.: Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog, 2011; 7:e1002106.
26.
ArcherJ, BravermanMS, TaillonBE, et al.: Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS, 2009; 23:1209–1218.
27.
SwensonLC, MoT, DongWW, et al.: Deep sequencing to infer HIV-1 co-receptor usage: Application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis, 2011; 203:237–245.
28.
HuangW, EshlemanSH, TomaJ, et al.: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol, 2007; 81:7885–7893.
29.
MorrisL, CilliersT, BredellH, PhoswaM, MartinDJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses, 2001; 17:697–701.
30.
MarmorM, SheppardHW, DonnellD, et al.: Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr, 2001; 27:472–481.
31.
ScribnerCL: CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med, 1998; 128:780.
32.
BrummeZL, GoodrichJ, MayerHB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis, 2005; 192:466–474.
33.
PeetersM, VincentR, PerretJL, et al.: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: Syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol, 1999; 20:115–121.
34.
GreenTN, ArcharyM, GordonML, et al.: Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses, 2012; 28:324–332.
35.
SinghA, SunpathH, GreenTN, et al.: Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: Implications for future treatment options. J Acquir Immune Defic Syndr, 2011:58:233–240.
36.
JohnstonER, ZijenahLS, MutetwaS, KantorR, KittinunvorakoonC, KatzensteinDA: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol, 2003; 77:7682–7688.
37.
HuntPW, HarriganPR, HuangW, et al.: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis, 2006; 194:926–930.
38.
HuangY, PaxtonWA, WolinskySM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med, 1996; 2:1240–1243.
39.
PaxtonWA, KangS, LiuR, et al.: HIV-1 infectability of CD4+ lymphocytes with relation to beta- chemokines and the CCR5 coreceptor. Immunol Lett, 1999; 66:71–75.
40.
PaxtonWA, LiuR, KangS, et al.: Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of beta-chemokines. Virology, 1998; 244:66–73.
41.
PastoreC, NedellecR, RamosA, et al.: Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol, 2007; 81:8165–8179.
42.
FerrerP, TelloM, MontecinosL, et al.: Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure. J Clin Virol, 2014; 60:290–294.
43.
LangeCG, ValdezH, MedvikK, AsaadR, LedermanMM: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol, 2002; 102:154–161.
44.
YangWL, KouyosRD, BoniJ, et al.: Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog, 2015; 11:e1004722.
45.
DappMJ, HeinemanRH, ManskyLM: Interrelationship between HIV-1 fitness and mutation rate. J Mol Biol, 2013; 425:41–53.
46.
BaatzF, StruckD, LemaireM, et al.: Rescue of HIV-1 long-time archived X4 strains to escape maraviroc. Antiviral Res, 2011; 92:488–492.
47.
MeijerinkH, IndratiAR, van CrevelR, JoostenI, KoenenH, van der VenAJ: The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: A cross-sectional study. BMC Infect Dis, 2014; 14:683.
48.
AlizonS, BoldinB: Within-host viral evolution in a heterogeneous environment: Insights into the HIV co-receptor switch. J Evol Biol, 2010; 23:2625–2635.
49.
van RijRP, HazenbergMD, van BenthemBH, et al.: Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS Res Hum Retroviruses, 2003; 19:389–398.
50.
RozeraG, AbbateI, BrusellesA, et al.: Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. AIDS, 2009; 23:2541–2543.
51.
ParisiSG, MazziR, BoldrinC, et al.: Drug-resistance mutations can be archived very early in HIV primary infection. AIDS, 2006; 20:1337–1338.
52.
TurrizianiO, BucciM, StanoA, et al.: Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr, 2007; 44:518–524.
53.
ReevesJ, HanD, LiuY, et al.: Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples. 11th European AIDS Conference/EACs, Madird, Spain, 2007.
54.
ConnorRI, ChenBK, ChoeS, LandauNR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology, 1995; 206:935–944.
55.
EdgarRC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res, 2004; 32:1792–1797.
56.
PriceMN, DehalPS, ArkinAP: FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol, 2009; 26:1641–1650.
57.
PriceMN, DehalPS, ArkinAP: FastTree 2—Approximately maximum-likelihood trees for large alignments. PLoS One, 2010; 5:e9490.
58.
KearseM, MoirR, WilsonA, et al.: Geneious basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics, 2012; 28:1647–1649.
59.
JordanMR, KearneyM, PalmerS, et al.: Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods, 2010; 168:114–120.
60.
EtemadB, Ghulam-SmithM, GonzalezO, WhiteLF, SagarM: Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics. J Virol Methods, 2015; 214:46–53.
61.
GuindonS, GascuelO: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol, 2003; 52:696–704.
62.
LeSQ, GascuelO: An improved general amino acid replacement matrix. Mol Biol Evol, 2008; 25:1307–1320.
63.
CurlinME, ZioniR, HawesSE, et al.: HIV-1 envelope subregion length variation during disease progression. PLoS Pathog, 2010; 6:e1001228.
64.
PetropoulosCJ, ParkinNT, LimoliKL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2000; 44:920–928.
65.
MohriH, PradaN, MarkowitzM: Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant. J Acquir Immune Defic Syndr, 2015; 68:487–494.
66.
CoetzerM, NedellecR, CilliersT, MeyersT, MorrisL, MosierDE: Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr, 2011; 56:9–15.
67.
MaldarelliF, KearneyM, PalmerS, et al.: HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J Virol, 2013; 87:10313–10323.
68.
MildM, KvistA, EsbjornssonJ, KarlssonI, FenyoEM, MedstrandP: Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol, 2010; 10:356–364.
69.
CuevasJM, GellerR, GarijoR, Lopez-AldeguerJ, SanjuanR: Extremely high mutation rate of HIV-1 in vivo. PLoS Biol, 2015; 13:e1002251.
70.
RothenbergerMK, KeeleBF, WietgrefeSW, et al.: Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A, 2015; 112:E1126–E1134.
71.
WagnerGA, PacoldME, Kosakovsky PondSL, et al.: Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis, 2014; 209:1032–1038.
72.
MildM, GrayRR, KvistA, et al.: High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. Infect Genet Evol, 2013; 19:369–377.
73.
SedeMM, MorettiFA, LauferNL, JonesLR, QuarleriJF: HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants. PLoS One, 2014; 9:e102857.
74.
HoSH, TascaS, ShekL, et al.: Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol, 2007; 81:8621–8633.
75.
MondorI, MoulardM, UgoliniS, et al.: Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology, 1998; 248:394–405.
76.
FoxDG, BalfeP, PalmerCP, MayJC, ArnoldC, McKeatingJA: Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Virol, 1997; 71:759–765.
77.
JanssonM, BackstromE, ScarlattiG, et al.: Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses, 2001; 17:1405–1414.
78.
WyattR, MooreJ, AccolaM, DesjardinE, RobinsonJ, SodroskiJ: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol, 1995; 69:5723–5733.
79.
ZhuangK, FinziA, TomaJ, et al.: Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology, 2012; 9:106.
80.
SechetM, RousselC, SchmitJL, et al.: X4 tropic virus prediction is associated with a nadir CD4 T-cell count below 100 cells/mm. Intervirology, 2015; 58:155–159.
81.
SiddiqueMA, HartmanKE, DragilevaE, et al.: Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis, 2006; 194:661–665.
82.
RibeiroRM, HazenbergMD, PerelsonAS, DavenportMP: Naive and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: Implications for therapy. J Virol, 2006; 80:802–809.
83.
HuntPW, MartinJN, SinclairE, et al.: T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis, 2003; 187:1534–1543.
84.
van RijRP, WorobeyM, VisserJA, SchuitemakerH: Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: Evidence for recombination. Virology, 2003; 314:451–459.
85.
MildM, EsbjornssonJ, FenyoEM, MedstrandP: Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: Implications for coreceptor switch. J Virol, 2007; 81:3369–3376.
86.
BazykinGA, DushoffJ, LevinSA, KondrashovAS: Bursts of nonsynonymous substitutions in HIV-1 evolution reveal instances of positive selection at conservative protein sites. Proc Natl Acad Sci U S A, 2006; 103:19396–19401.
87.
BelloG, CasadoC, GarciaS, et al.: Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naive patients. Virology, 2007; 362:294–303.
88.
HarringtonPR, NelsonJA, KitrinosKM, SwanstromR: Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol, 2007; 81:5413–5417.
89.
KitchenCM, PhilpottS, BurgerH, WeiserB, AnastosK, SuchardMA: Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral therapy: A Bayesian approach. J Virol, 2004; 78:11296–11302.
90.
MostowyR, KouyosRD, FouchetD, BonhoefferS: The role of recombination for the coevolutionary dynamics of HIV and the immune response. PLoS One, 2011; 6:e16052.
91.
ShiB, KitchenC, WeiserB, et al.: Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology, 2010; 404:5–20.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
